Jixing Pharmaceuticals Enrolls First Patient in Etripamil Phase III Study for PSVT
China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III...
Drug
Takeda’s Obizur Prioritized for Review in Acquired Hemophilia A Treatment
The Center for Drug Evaluation (CDE) website indicates that Takeda Pharmaceutical Co., Ltd’s Obizur (susoctocog...
Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for First-Line NSCLC Treatment
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that it has received another indication approval from...
Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...
Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...
Jixing Pharmaceuticals’ Aficamten Receives CDE Approval for Phase III HCM Study
China-based Ji Xing Pharmaceuticals announced receiving approval from the Center for Drug Evaluation (CDE) to...
BDgene Advances CRISPR-Based BD111 for Herpes Keratitis with IND Filing
Shanghai BDgene Technology Co., Ltd has completed efficacy and preliminary safety studies for BD111, its...
Bayer’s Kerendia Approved by China’s NMPA for Diabetic Kidney Disease
The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia...
Hengrui Medicine’s SHR3680 Approved for High Burden Metastatic Prostate Cancer
China’s Hengrui Medicine Co., Ltd. (SHA: 600276) announced that its Category 1 drug SHR3680 has...
Akeso Biopharma’s Cadonilimab Approved for Cervical Cancer Treatment
China-based biotech company Akeso Biopharma (HKG: 9926) announced that its self-discovered bispecific antibody (BsAb) cadonilimab...
Humanwell Healthcare Wins NMPA Approval for RFUS-144 in Pain Management
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced receiving approval from the National Medical...
Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China
The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...
Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines
China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food...
Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment
US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa...
Clover Biopharmaceuticals’ SCB-2019 COVID-19 Vaccine Shows Strong Immune Response in Third Shot Study
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has published clinical data for its COVID-19 vaccine candidate...
Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials
China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA...
Sinovac Biotech’s CoronaVac Receives Conditional Registration from South African Regulator
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced that the South African Health Products Regulatory...
Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...
Ascletis Pharma Presents ASC22 Phase IIb Results for Chronic Hepatitis B at ILC 2022
China-based Ascletis Pharma Inc. (HKG: 1672) presented the latest results of a Phase IIb clinical...
Cosunter Pharma’s HBV Surface Antigen Inhibitor GST-HG121 Approved for Phase I Trial
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced receiving approval from the ethics...